Latest news with #MediPharm
The Market Online
13 hours ago
- Business
- The Market Online
The 5-Minute Investor Podcast, Ep. 13: A full breath of cannabis stocks
Welcome to episode 13 of The 5-Minute Investor Podcast, where Stockhouse columnists Jonathon Brown and Trevor Abes each deliver a 2.5-minute stock pick related to recent news stories with investment implications. Here is Jon's article for episode 13: What is going on with MediPharm Labs? (Stockhouse). Jon's stock pick for this week is MediPharm Labs (TSX:LABS), a developer and manufacturer of pharmaceutical-grade cannabis concentrates, active pharmaceutical ingredients and advanced derivative products. At the time of writing, MediPharm stock last traded at C$0.075, giving back 6.25 per cent year-over-year and 95.99 per cent since 2020. Here are Trevor's articles: Here's a list of past episodes: Thanks for listening! The 5-Minute Investor is on Spotify, YouTube, iHeartRadio, Podbean, Stockhouse or wherever finer podcasts are found. Join the discussion: Find out what investors are saying about The 5-Minute Investor Podcast and this week's stock picks on the MediPharm Labs Corp. and Cannabix Technologies Inc. Bullboards and check out the rest of Stockhouse's stock forums and message boards. The material provided in this podcast is for information only and should not be treated as investment advice. For full disclaimer information, please click here. (Top image: Adobe Stock)
Yahoo
15 hours ago
- Business
- Yahoo
Leading Independent Proxy Advisor ISS Recommends that Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees; REJECTS Apollo's Arguments and Director Slate
ISS concludes that Apollo 'has not presented a compelling case for change' TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ('MediPharm' or the 'Company'), a pharmaceutical company specialized in precision-based cannabinoids, today announced that Institutional Shareholder Services ('ISS') published a report on May 30, 2025 (the 'ISS Report') recommending that MediPharm shareholders vote the GREEN Proxy or voting instruction form FOR the Company's nominees for the Board of Directors (the 'Board') at the upcoming Annual and Special Meeting of Shareholders on June 16, 2025 (the 'Meeting'). ISS is a leading independent proxy voting and corporate governance advisory firm whose recommendations are trusted by pension funds, investment managers, mutual funds, and other institutional shareholders. The ISS Report concludes: 'As the dissident has not presented a compelling case for change, shareholders are recommended to vote FOR all management nominees.' The ISS Report further recommended that MediPharm shareholders DO NOT VOTE on the gold dissident proxy card as Apollo did not provide a compelling case for change. Chris Taves, Chair of MediPharm, commented, 'We are very pleased that an independent proxy advisory firm has taken the time to meet with both parties to hear our respective arguments, and has recommended voting in favour of management's director nominees. Shareholders have been subjected to a large volume of information from both the Company and the dissident in recent weeks, and we believe the ISS Report reinforces our consistent position that Apollo has been flooding the market with misinformation and unsupportable statements. It is also encouraging that ISS has recognized the turnaround of our business that has been facilitated under the leadership of CEO David Pidduck. The Board truly believes that there is momentum in our business and that once we can overcome the costly distraction of this proxy contest, we can return our complete focus to strategic growth opportunities.' Key Conclusions in the ISS Report In explaining the reasons for its recommendation, the ISS Report reviews each of Apollo's major claims and concludes that there is insufficient evidence to support any of them. Statements in the ISS Report that refute Apollo's claims include the following: 'Since Q2 2022, quarterly revenues have more than doubled, adjusted EBITDA has swung from a $6.3 million loss to a $0.1 million gain, gross margins have expanded 50.9 percentage points over Q2 2022, and the company's SG&A has remained fairly stable. Against this backdrop, it is challenging to validate the dissident's claims that the company's costs have 'ballooned' or that revenue is 'imploding'. In particular, it also seems incorrect to suggest the company has experienced poor post-acquisition integration over a period where revenues and gross margins have risen dramatically while SG&A expenses have remained relatively flat.' 'LABS has experienced multiple years of improving financial results, which overlap with Pidduck's tenure as CEO as well as a series of acquisitions and non-core asset divestitures. Management has communicated a logical strategy that focuses on higher margin, international markets where the company can leverage a competitive advantage. Moreover, there does not appear to be sufficient evidence that the company is in imminent danger of running out of cash.' '… the company has generally outperformed peers and experienced a clear operational turnaround. Meanwhile, the dissident's assertions about the company's peril are not able to be sufficiently validated with available information. As such, the dissident has not presented a case for board change.' '… a review of [Total Shareholder Return] over [Pidduck's] tenure shows that the company has outperformed its peer group and [the Global X Marijuana Life Sciences Index ETF HMMJ] … There is limited utility focusing on absolute performance as the entire sector has suffered tremendous losses. In this context, it can be recognized that since 2022, LABS has managed to reverse course and separate itself positively from most peers.' 'Based on the company's improving financial performance since the VIVO acquisition and the manner in which redundant assets are being monetized to improve balance sheet strength, it is difficult to conclude that the company has engaged in reckless M&A.' 'The dissident has presented serious claims about concerns with the board's management oversight capabilities and executive compensation practices. At this time, there does not appear to be a conclusive deficiency in corporate governance and the company has provided valid explanations for its compensation practices.' The ISS Report summarizes the high standard required of any dissident seeking to replace an entire board of directors: 'When analyzing proxy contests, ISS focuses on two central questions: Has the dissident made a compelling case that change is warranted? If so, are the dissident nominees more likely to effect that change than the incumbent directors?' 'When the dissident is seeking board control, ISS looks for a well-reasoned and detailed business plan (including the dissident's strategic initiatives), a transition plan that describes how the change in control of the company will be effected, and where management continuity may be an issue, the identification of a qualified and credible new management team.' The ISS Report then reaches a clear conclusion on its recommendation for the election of directors: 'As there is no case for change at this time, shareholders are recommended to vote FOR all management nominees.' The ISS Report further recommends that shareholders vote for the resolution to fix the number of directors at seven, and vote for the resolution to approve MNP LLP as auditors and authorize the Board to fix their remuneration. The ISS Report also recommends that shareholders vote against the resolution to approve all unallocated awards under the Company's equity incentive plan. The independent Compensation Committee of the Board will continue to regularly review the Company's compensation policies. Vote for the Highly Qualified MediPharm Nominees MediPharm urges shareholders to vote only using the GREEN proxy or GREEN voting instruction form in support of all of the Company's nominees and resolutions. To ensure your vote is counted, shareholders are encouraged to proactively contact their broker to obtain their 16-digit control number associated with the GREEN management proxy. Once received, you can cast your vote by visiting . You may receive materials or outreach from the dissident — please disregard any such communications and vote only using the GREEN proxy in support of the Company's nominees. About MediPharm Labs Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company's current foreign drug manufacturing site registration with the US FDA. In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce platform, and in Australia and Germany through Beacon Medical Australia PTY Ltd. and Beacon Medical Germany GMBH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with Physician consultations for medical cannabis education and prescriptions. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates. Shareholder Voting Assistance: If you have any questions or require any assistance in executing your GREEN proxy or voting instruction form, please call Sodali & Co at: North American Toll-Free Number: 1.888.777.2059Outside North America, Banks, Brokers and Collect Calls: 1.289.695.3075Email: assistance@ American Toll-Free Facsimile: 1.877.218.5372 For up-to-date information and assistance in voting please visit: Investor Contact: MediPharm Labs Investor RelationsTelephone: +1 416.913.7425Email: investors@ Media Contact: John VincicOakstrom Advisors+1 (647) 402-6375john@ Cautionary Note Regarding Forward-Looking Information: This news release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking statements') within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as 'expects', or 'does not expect', 'is expected', 'anticipates' or 'does not anticipate', 'plans', 'budget', 'scheduled', 'forecasts', 'estimates', 'believes' or 'intends' or variations of such words and phrases or stating that certain actions, events or results 'may' or 'could', 'would', 'might' or 'will' be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things: timing of the Annual and Special Meeting, any potential momentum in the Company's business, the ability of the Company to capitalize on strategic growth opportunities, and any outcomes resulting from the circumstances and information cited herein. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs' continuous disclosure filings, available on the SEDAR+ website at There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
Yahoo
3 days ago
- Business
- Yahoo
MediPharm Labs Refuses to Answer Direct Questions Regarding Credible Securities Fraud Allegations Says Apollo Capital
Demands Management's Board Nominees John Medland and Emily Jameson Withdraw Immediately or Face Public Complicity in Ongoing Alleged Systemic Violations of Securities LawsTORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- Apollo Technology Capital Corporation ('Apollo Capital'), which together with its affiliates and associates collectively is one of the largest shareholders of MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ('MediPharm', 'MediPharm Labs', or the 'Company'), owning approximately 3% of the Company's common stock, today condemned MediPharm Labs and its leadership team for their blatant failure and outright refusal to answer simple, direct, and highly serious questions concerning credible allegations of alleged extensive securities act disclosure violations committed by the MediPharm Labs' Board of Directors (the 'Board') and management team. In a deeply troubling display of evasion and obfuscation, MediPharm Labs' senior management and current board—including Chairman Chris Taves (Managing Director and Head of Capital Markets for Asia at BMO), CEO David Pidduck (former CEO of OxyContin® Manufacturer Purdue Pharma), Shelley Potts, Chris Halyk, Keith Strachan, and recently resigned Audit Committee Chair Michael Bumby—have persistently refused to respond meaningfully to allegations of systemic and intentional securities fraud. Apollo Capital asks incoming MediPharm Labs Board nominees John Medland and Emily Jameson: How long will you continue standing for election to a board that consistently refuses to answer basic questions about credible allegations of securities fraud? Are you prepared to potentially permanently stain your professional reputations by associating yourselves with an entity that has been accused of deliberately evading accountability and transparency? Apollo Capital demands immediate, straightforward answers from MediPharm's directors to the following questions: Has MediPharm Labs changed its revenue recognition practices from those in place two years ago? Is any purported growth simply a result of creative accounting designed to deceive shareholders? Given the undeniable gravity and credible evidence surrounding these allegations, Apollo Capital reiterates its urgent call for an immediate, comprehensive investigation by regulatory authorities including the Ontario Securities Commission (OSC), the Toronto Stock Exchange (TSX), and the U.S. Securities and Exchange Commission (SEC). Earlier this week, Apollo Capital raised broader concerns about the current Board's commitment to ethical conduct, asking its fellow shareholders if they felt like Chairman Chris Taves properly fulfilled his fiduciary and moral duties and obligations to make them fully aware of David Pidduck's history as CEO and VP of Marketing for OxyContin® Manufacturer Purdue Pharma, and whether they felt like details of Pidduck's very recent past were MATERIAL facts that Chairman Taves should have made crystal clear before asking them on multiple occasions to vote in favour of Pidduck's outrageous and off-market compensation package. Apollo Capital's nominees, experienced professionals known for corporate turnarounds, have clearly outlined their mission: to root out any corporate rot, restore credibility, and return value to shareholders. MediPharm Labs shareholders deserve accountability, transparency and competent leadership—not empty claims, evasive tactics and an almost complete destruction of investor value. Previous Apollo Capital press releases detailing allegations of fraudulent and unethical activities at MediPharm Labs can be accessed here: Alleged Securities Fraud at MediPharm Labs Says Apollo Capital (May 29, 2025) Apollo Capital Calls Out MediPharm Chairman Chris Taves (Managing Director, BMO Capital Markets) for Failure to Properly Communicate to Shareholders Details of David Pidduck's Past as CEO and VP of Marketing for OxyContin® Manufacturer Purdue Pharma (May 27, 2025) Apollo Capital Comments on MediPharm Labs' Failure to Respond to Reasonable Offer to Ensure Fair, Lawful and Transparent 2025 Annual Meeting (May 23, 2025) MediPharm Labs Shareholders can visit to sign up for important campaign updates. To access Apollo Capital's Circular and related proxy materials, including a proxy or voting instruction form, visit SEDAR+ at Contacts For Shareholders:Carson ProxyNorth American Toll-Free Phone: 1-800-530-5189Local or Text Message: 416-751-2066 (collect calls accepted)E: info@ For Media:CureMediPharm@ Legal Disclosures Information in Support of Public Broadcast Exemption under Canadian Law In connection with the Annual Meeting, Apollo Capital has filed an amended and restated dissident information circular (the "Circular") in compliance with applicable corporate and securities laws. Apollo Capital has provided in, or incorporated by reference into, this press release the disclosure required under section 9.2(4) of NI 51-102 – Continuous Disclosure Obligations ("NI 51-102") and the corresponding exemption under the Business Corporations Act (Ontario), and has filed the Circular, available under MediPharm's profile on SEDAR+ at The Circular contains disclosure prescribed by applicable corporate law and disclosure required under section 9.2(6) of NI 51-102 in respect of Apollo Capital's director nominees, in accordance with corporate and securities laws applicable to public broadcast solicitations. The Circular is hereby incorporated by reference into this press release and is available under MediPharm's profile on SEDAR+ at The registered office of the Company is 151 John Street, Barrie, Ontario, Canada L4N 2L1. SHAREHOLDERS OF MEDIPHARM ARE URGED TO READ THE CIRCULAR CAREFULLY BECAUSE IT CONTAINS IMPORTANT INFORMATION. Investors and shareholders are able to obtain free copies of the Circular and any amendments or supplements thereto and further proxy circulars at no charge under MediPharm's profile on SEDAR+ at In addition, shareholders are also able to obtain free copies of the Circular and other relevant documents by contacting Apollo Capital's proxy solicitor, Carson Proxy Advisors Ltd. ("Carson Proxy") at 1-800-530-5189, local (collect outside North America): 416-751-2066 or by email at info@ Proxies may be revoked in accordance with subsection 110(4) of the Business Corporations Act (Ontario) by a registered shareholder of Company shares: (a) by completing and signing a valid proxy bearing a later date and returning it in accordance with the instructions contained in the accompanying form of proxy; (b) by depositing an instrument in writing executed by the shareholder or by the shareholder's attorney authorized in writing; (c) by transmitting by telephonic or electronic means a revocation that is signed by electronic signature in accordance with applicable law, as the case may be: (i) at the registered office of the Company at any time up to and including the last business day preceding the day the Annual Meeting or any adjournment or postponement of the Annual Meeting is to be held, or (ii) with the chair of the Annual Meeting on the day of the Annual Meeting or any adjournment or postponement of the Annual Meeting; or (d) in any other manner permitted by law. In addition, proxies may be revoked by a non-registered holder of Company shares at any time by written notice to the intermediary in accordance with the instructions given to the non-registered holder by its intermediary. It should be noted that revocation of proxies or voting instructions by a non-registered holder can take several days or even longer to complete and, accordingly, any such revocation should be completed well in advance of the deadline prescribed in the form of proxy or voting instruction form to ensure it is given effect in respect of the Annual Meeting. The costs incurred in the preparation and mailing of any circular or proxy solicitation by Apollo Capital and any other participants named herein will be borne directly and indirectly by Apollo Capital. However, to the extent permitted under applicable law, Apollo Capital intends to seek reimbursement from the Company of all expenses incurred in connection with the solicitation of proxies for the election of its director nominees at the Annual Meeting. This press release and any solicitation made by Apollo Capital is, or will be, as applicable, made by such parties, and not by or on behalf of the management of the Company. Proxies may be solicited by proxy circular, mail, telephone, email or other electronic means, as well as by newspaper or other media advertising and in person by managers, directors, officers and employees of Apollo Capital who will not be specifically remunerated therefor. In addition, Apollo Capital may solicit proxies by way of public broadcast, including press release, speech or publication and any other manner permitted under applicable Canadian laws, and may engage the services of one or more agents and authorize other persons to assist it in soliciting proxies on their behalf. Apollo Capital has entered into an agreement with Carson Proxy Advisors ("Carson Proxy") for solicitation and advisory services in connection with the solicitation of proxies for the Meeting, for which Carson Proxy will receive a fee not to exceed $250,000, together with reimbursement for reasonable and out-of-pocket expenses. Apollo Capital has also engaged Gasthalter & Co. LP ("G&Co") to act as communications consultant to provide Apollo Capital with certain communications, public relations and related services, for which G&Co will receive a minimum fee of US$75,000 in addition to a performance fee of US$250,000 in the event that Apollo Capital's nominees make up a majority of the Board following the Annual Meeting, plus excess fees, related costs and expenses. No member of Apollo Capital nor any of their associates or affiliates has or has had any material interest, direct or indirect, in any transaction since the beginning of the Company's last completed financial year or in any proposed transaction that has materially affected or will or would materially affect the Company or any of the Company's affiliates. No member of Apollo Capital nor any of their associates or affiliates has any material interest, direct or indirect, by way of beneficial ownership of securities or otherwise, in any matter to be acted upon at the Annual Meeting, other than setting the number of directors, the election of directors, the appointment of auditors and the approval of the ordinary resolution approving, among other things, the Company's amended and restated equity incentive plan dated May 8, 2025 and the unallocated awards available thereunder. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward‐looking statements. All statements contained in this filing that are not clearly historical in nature or that necessarily depend on future events are forward‐looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward‐looking statements. These statements are based on current expectations of Apollo Capital and currently available information. They are not guarantees of future performance, involve certain risks and uncertainties that are difficult to predict, and are based upon assumptions as to future events that may not prove to be accurate. All forward-looking statements contained herein are made only as of the date hereof and Apollo Capital disclaims any intention or obligation to update or revise any such forward-looking statements to reflect events or circumstances that subsequently occur, or of which Apollo Capital hereafter becomes aware, except as required by applicable law. Hashtags: #ShareholderActivism #CorporateGovernance #InvestorProtection #Investor Alert #Investor Fraud #FinancialRegulation #CorporateCrime #FinancialCrime #HomelandSecurity #DHS #OpioidCrisis #OpioidEpidemic #OpioidLitigation #OpioidVictims #BMO #DEA #ONDCP
Yahoo
4 days ago
- Business
- Yahoo
MediPharm Labs Responds to Fabricated Allegations from Dissident Shareholder
TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE:MLZ) ('MediPharm' or the 'Company'), a pharmaceutical company specialized in precision-based cannabinoids, today confirmed that the Company is aware of the news release issued by Apollo Technology Capital Corporation ('Apollo') on May 29, 2025 making baseless allegations of malfeasance against the Company. These patently false allegations have been intentionally or recklessly fabricated as part of the campaign of misinformation employed by Apollo and its Chairman and CEO, Regan McGee in their bid to distract and mislead the Company's shareholders and parlay their 3% ownership position into total control of MediPharm's Board of Directors. MediPharm recently completed a full year-end audit with MNP LLP and received a clean audit opinion dated March 30, 2025, as it has in all previous fiscal years since becoming a public company. Public companies are not required to audit their quarterly financial results nor is it market practice to do so. The Company complies fully with International Financial Reporting Standards and its continuous disclosure obligations pursuant to Canadian securities law. MediPharm has commenced legal proceedings this week to address, in part, material misstatements Apollo has been making and has asked the court to award its costs. About MediPharm Labs Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company's current foreign drug manufacturing site registration with the US FDA. In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce platform, and in Australia and Germany through Beacon Medical Australia PTY Ltd. and Beacon Medical Germany GMBH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with Physician consultations for medical cannabis education and prescriptions. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates. Shareholder Voting Assistance: If you have any questions or require any assistance in executing your GREEN proxy or voting instruction form, please call Sodali & Co at: North American Toll-Free Number: 1.888.777.2059Outside North America, Banks, Brokers and Collect Calls: 1.289.695.3075Email: assistance@ American Toll-Free Facsimile: 1.877.218.5372 For up-to-date information and assistance in voting please visit: Investor Contact: MediPharm Labs Investor RelationsTelephone: +1 416.913.7425Email: investors@ Media Contact: John VincicOakstrom Advisors+1 (647) 402-6375john@ Cautionary Note Regarding Forward-Looking Information: This news release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking statements') within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as 'expects', or 'does not expect', 'is expected', 'anticipates' or 'does not anticipate', 'plans', 'budget', 'scheduled', 'forecasts', 'estimates', 'believes' or 'intends' or variations of such words and phrases or stating that certain actions, events or results 'may' or 'could', 'would', 'might' or 'will' be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, the outcome of litigation commenced by MediPharm, and any outcomes resulting from the circumstances and information cited herein. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs' continuous disclosure filings, available on the SEDAR+ website at There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Market Online
4 days ago
- Business
- The Market Online
Buzz on the Bullboards: Bombardier vs Boeing, MediPharm 'under attack'
Even with Wall Street operating on a shortened schedule due to the Memorial Day holiday, the TSX has shown resilience—hitting fresh highs twice this week. This bullish momentum underscores the strength and diversity of Canadian equities, particularly in sectors like pharmaceuticals, aerospace, and advanced manufacturing. Among the standout performers are three companies capturing investor attention with bold moves and strategic milestones: MediPharm Labs, Bombardier, and PyroGenesis. MediPharm Labs (TSX:LABS, Forum), a pharmaceutical business in precision-based cannabinoids, has announced the commencement of production for its novel cannabis metered dose inhalers (MDIs) aimed at the European Union and United Kingdom markets. These discreet, smoke-free devices offer patients a fast-acting, pharmaceutical-grade alternative to traditional cannabis consumption methods. What the 'Buzz' Our Bullboards have up to 2 million pageviews a day. Get the inside scoop on conversations around the most significant trends and stock appreciations in our weekly wrap up. Get 'Buzz on the Bullboards' delivered to your inbox every third Thursday! Buzz on the Bullboards | Sign Up Here Manufactured under stringent Good Manufacturing Practices (GMP), the MDIs are distributed exclusively by Blackpoint Ltd., MediPharm's regional partner. The company has already launched the product in Canada and anticipates further rollouts in Australia, the EU, and the UK by Q3 2025. This expansion comes on the heels of a $4.5 million cash sale of its Hope facility, a move aimed at streamlining operations. However, internal turbulence looms. A proxy battle with dissident shareholder Apollo Technology Capital Corp. has raised concerns about governance and financial stability. Despite these headwinds, MediPharm reported an 11 per cent revenue increase in Q1, signaling operational momentum amid strategic uncertainty. MediPharm published a response, calling Apollo Capital 'dissidents' and they 'do not believe they are the well-intentioned and successful business leaders they portray themselves to be', saying the company is currently 'under attack'. Bombardier (TSX:BBD, Forum) has reached a major milestone in its Global 8000 program, with the first production aircraft completing its inaugural flight on May 16. Departing from the company's Aircraft Assembly Centre in Mississauga, Ontario, the flight marks a pivotal step toward the aircraft's entry into service in the second half of 2025. The Global 8000 is positioned as the next evolution of the Global 7500, offering a top speed of Mach 0.94 and an industry-leading range of 8,000 nautical miles. It's designed to connect global cities like Singapore to Los Angeles and London to Perth without refueling, while also offering access to shorter runways typically reserved for smaller jets. Inside, the aircraft redefines luxury with four true living spaces, a dedicated crew rest area, and the lowest cabin altitude in its class. With over 250,000 flight hours logged by the Global 7500, Bombardier's latest innovation is poised to capture a significant share of the ultra-long-range business jet market. Advanced materials innovator PyroGenesis (TSX:PYR, Forum) has secured a major endorsement from aerospace giant Boeing (NYSE:BA, Forum). The company's Ti64 'coarse' metal powder—used in additive manufacturing—has been officially approved and added to Boeing's qualified supplier list. This qualification is a significant validation of PyroGenesis' proprietary plasma atomization technology, which produces high-purity metal powders for 3D printing in aerospace and defense applications. The approval opens the door to broader adoption of PyroGenesis' materials in Boeing's manufacturing ecosystem, potentially unlocking new revenue streams and long-term contracts. As the aerospace industry increasingly turns to additive manufacturing for lightweight, high-performance components, PyroGenesis is well-positioned to benefit from this structural shift. These three TSX-listed companies—MediPharm Labs, Bombardier, and PyroGenesis—are each making headlines for different reasons, from product innovation and international expansion to strategic partnerships and shareholder activism. While the TSX continues to climb, investors would be wise to dig deeper into these stories, assess the risks and opportunities, and consider how these developments align with their investment goals. As always, thorough due diligence remains the cornerstone of smart investing. For previous editions of Buzz on the Bullboards, click here. Join the discussion: Find out what everybody's saying about these stock on Stockhouse's stock forums and message boards. The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
